Resultado de búsqueda
Hace 5 días · A young boy enrolled in a clinical trial testing an experimental Pfizer gene therapy for Duchenne muscular dystrophy has died, the company revealed Tuesday in a letter posted online by a patient advocacy group. The boy, who received the therapy in early 2023 as part of a Phase 2 study, “passed away suddenly,” the letter said.
Hace 4 días · May 08, 2024 | staff reporter. Save for later. NEW YORK – A young boy who had received Pfizer's gene therapy candidate for Duchenne muscular dystrophy (DMD) has died, according to a letter written by the team at Pfizer developing the agent and shared by the patient advocacy group Parent Project Muscular Dystrophy.
Hace 4 días · May 7, 2024 at 1:27 PM PDT. Listen. 1:15. Pfizer Inc. paused a study of an experimental gene therapy for muscular dystrophy after a child who received it died suddenly. The patient, a young...
Hace 4 días · A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a...
Hace 5 días · A young boy with Duchenne muscular dystrophy (DMD) participating in Pfizer’s phase 2 gene therapy trial has died, the pharma shared in a May 7 letter (PDF) cited by nonprofit Parent Project...
Hace 4 días · The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to pause dosing in another...
Hace 5 días · By Thomson Reuters May 7, 2024 | 5:05 PM. (Reuters) – A young boy died due to a cardiac arrest in a mid-stage trial that tested Pfizer’s experimental gene therapy for a muscle-wasting disorder called Duchenne muscular dystrophy (DMD), the drugmaker told Reuters on Tuesday.
